Almeda Pharmaceuticals Ag
Almeda Pharmaceuticals AG is a privately held Swiss specialty pharmaceutical company that distributes branded generic oncology drugs and rare disease therapies through exclusive licensing partnerships across 10 CIS countries, serving hospitals, pharmacies, and wholesalers under a Swissmedic license.
- Company typePrivate
- Founded2013
- HeadquartersZug, Switzerland
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Almeda Pharmaceuticals Ag does
Almeda Pharmaceuticals AG is a privately held Swiss specialty pharmaceutical company founded in 2013 and headquartered in Zug, Switzerland. The company distributes branded generic oncology products under the MEDA line (Camptomeda/Irinotecan, Docemeda/Docetaxel, Eloxamada/Oxaliplatin, Fludameda/Fludarabin, Gemcimeda/Gemcitabin, Rubimeda/Epirubicin, Taxomeda/Paclitaxel, Velbimeda/Vinorelbine, and Zolemeda/Zoledronic Acid), and supplies specialty pharmaceuticals across Transplanthology, CNS, Antimicrobic, and food supplement categories. Through 2023-2024 exclusive partnerships with Callion Pharma (rare disease therapies, Cystic Fibrosis) and Galen Pharma (PKU EASY Microtabs Plus for Phenylketonuria), Almeda is extending into branded rare disease products for the CIS region.
The company holds a Swissmedic license for pharmaceutical activities (wholesaler and sales outside Switzerland) and operates a GDP-compliant quality management system. Its go-to-market is B2B channel partner distribution: Almeda acquires exclusive licensing and distribution rights from international manufacturers and supplies hospitals, pharmacies, and wholesalers across 10 CIS countries (Moldova, Ukraine, Armenia, Azerbaijan, Georgia, Kazakhstan, Uzbekistan, Turkmenistan, Tajikistan, and Kyrgyzstan). Revenue is generated through licensing/royalty arrangements, sale of branded generic products, and market entry services for international pharmaceutical manufacturers seeking CIS access, including regulatory compliance and supply chain management.
The firm's only disclosed executive is CEO Ala Tocarciuc. Almeda is privately held by its founders, with no disclosed venture capital, private equity, or public market backing. No headcount, revenue, or funding figures are publicly available, and the company has no disclosed AI/ML technology stack; its competitive position rests on CIS regulatory expertise, exclusive territorial licenses, and a Swiss regulatory base of operations.
Almeda Pharmaceuticals Ag firmographics
Firmographics- Name
- Almeda Pharmaceuticals Ag
- Legal name
- Almeda Pharmaceuticals AG
- Website
- https://almedapharma.ch
- Company type
- Private
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Almeda Pharmaceuticals AG is a privately held Swiss specialty pharmaceutical company that distributes branded generic oncology drugs and rare disease therapies through exclusive licensing partnerships across 10 CIS countries, serving hospitals, pharmacies, and wholesalers under a Swissmedic license.
- Ownership category
- akta.pro rank
Almeda Pharmaceuticals Ag industry classification
Industry- Product category
- Specialty Pharmaceutical Distribution & Licensing
- NAICS
- Drugs and Druggists' Sundries Merchant Wholesalers (424210)
- SIC
- Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Specialty Pharmacy & Biologics Distribution (CRAOAHAD)
- akta.pro secondary industries
- Specialty Pharma & Biologics Distribution (GDP-compliant) (HLAGAMAD), Specialty Care Pharmaceuticals (HLAIAAAB), Generic Hospital & Institutional Products (HLAIABAL)
Keywords
Where Almeda Pharmaceuticals Ag is headquartered
LocationHeadquarters
- HQ city
- Zug
- HQ country
- Switzerland
- HQ region
- Europe
Offices1 record
Markets served
Almeda Pharmaceuticals Ag business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales
Revenue model
- Licensing and Distribution Rights: Almeda Pharmaceuticals AG generates revenue through acquiring exclusive licensing rights to distribute pharmaceutical products in the CIS region, including specialty drugs for rare diseases and food supplements.
- Generic Pharmaceutical Products: Sale of generic pharmaceutical products including oncology medications (Irinotecan, Docetaxel, Oxaliplatin, Gemcitabin, Paclitaxel, etc.), specialty pharma, and food supplements.
- Market Entry Services: Providing comprehensive market entry services in the CIS region, including regulatory compliance, distribution and supply chain management, and market access facilitation for international pharmaceutical manufacturers.
Go-to-market motion3 records
Distribution channels3 records
Marketing channels3 records
Almeda Pharmaceuticals Ag product offering
Product offeringCore offering
Almeda Pharmaceuticals AG is a Swiss specialty pharmaceutical company that acquires exclusive licensing and distribution rights to international pharmaceutical products and distributes them across the CIS region. Its portfolio spans branded generic oncology drugs (the MEDA line), transplanthology, CNS, antimicrobic, and rare disease therapies, complemented by food supplements. The company also provides regulatory, supply-chain, and market-access services to manufacturers seeking entry into Eastern European and Central Asian markets.
Product overview
Almeda Pharmaceuticals AG is a Swiss pharmaceutical company founded in 2013, headquartered in Zug, Switzerland, operating as a specialty pharma company focused on oncology, rare diseases, and food supplements. The product portfolio centers on the MEDA product line (Camptomeda, Docemeda, Eloxamada, Fludameda, Gemcimeda, Rubimeda, Taxomeda, Velbimeda, Zolemeda) - branded generic oncology medications covering Irinotecan, Docetaxel, Oxaliplatin, Fludarabin, Gemcitabin, Epirubicin, Paclitaxel, Vinorelbine, and Zoledronic Acid. The company also offers specialty pharma in Transplanthology, CNS, and Antimicrobic categories; rare disease treatments including small molecules, monoclonal antibodies (MAB), and cell therapy; and consumer health products including vitamins, dietary supplements, and foods for special medical purposes. Through partnerships, Almeda distributes licensed products like PKU EASY Microtabs Plus for Phenylketonuria. The company operates primarily in CIS markets (Ukraine, Moldova, Georgia, Armenia, Azerbaijan, Kazakhstan, Uzbekistan, Turkmenistan, Tajikistan, Kyrgyzstan) with a holistic project management approach from product entry to market.
Differentiator
Problem solved
Functional benefit
Brands
- CAMPTOMEDA: Irinotecan - oncology product
- DOCEMEDA
- ELOXAMEDA
- FLUDAMEDA
- GEMCIMEDA
- RUBIMEDA
- TAXOMEDA
- VELBIMEDA
- ZOLEMEDA
Products and services
- Camptomeda (Irinotecan) Oncology medication; Camptomeda is Almeda's branded generic version of Irinotecan, a topoisomerase inhibitor used in cancer treatment, supplied via the company's CIS region distribution network to healthcare providers.
- Docemeda (Docetaxel) Oncology medication; Docemeda is Almeda's branded generic version of Docetaxel, a chemotherapy agent used for various cancers, supplied through the CIS distribution network.
- Eloxamada (Oxaliplatin) Oncology medication; Eloxamada is Almeda's branded generic version of Oxaliplatin, a platinum-based chemotherapy drug, supplied via the CIS distribution channel.
- Fludameda (Fludarabin) Oncology medication; Fludameda is Almeda's branded generic version of Fludarabin, a purine analog used in chemotherapy, sold through the CIS distribution network.
- Gemcimeda (Gemcitabin) Oncology medication; Gemcimeda is Almeda's branded generic version of Gemcitabin, a nucleoside analog used in pancreatic, lung, and bladder cancer treatment, supplied through CIS distribution.
- Rubimeda (Epirubicin) Oncology medication; Rubimeda is Almeda's branded generic version of Epirubicin, an anthracycline chemotherapy drug, supplied through the CIS distribution network.
- Taxomeda (Paclitaxel) Oncology medication; Taxomeda is Almeda's branded generic version of Paclitaxel, a microtubule-stabilizing agent used in breast, ovarian, and lung cancers, distributed across the CIS region.
- Velbimeda (Vinorelbine) Oncology medication; Velbimeda is Almeda's branded generic version of Vinorelbine, a vinca alkaloid chemotherapy agent, supplied through the CIS distribution network.
- Zolemeda (Zoledronic Acid) Oncology medication; Zolemeda is Almeda's branded generic version of Zoledronic Acid, a bisphosphonate used to treat bone metastases and hypercalcemia, supplied via CIS distribution.
- PKU EASY Microtabs Plus Phenylalanine-free protein substitute enriched with vitamins, minerals, and essential and non-essential amino acids for individuals with Phenylketonuria (PKU); licensed from Galen Pharma for distribution by Almeda across six CIS markets.
- Specialty Pharma - Transplanthology Specialty pharmaceutical products for transplanthology that support patients undergoing organ transplantation, distributed to healthcare providers across CIS countries.
- Specialty Pharma - CNS Specialty pharmaceutical products addressing central nervous system disorders, distributed to healthcare providers in CIS markets.
- Specialty Pharma - Antimicrobic Specialty pharmaceutical products with antimicrobial properties distributed to healthcare providers in CIS markets.
- Callion Pharma Rare Disease Therapies (Cystic Fibrosis) Innovative rare disease therapies licensed from Callion Pharma (USA) and distributed by Almeda exclusively across the CIS region for Cystic Fibrosis patients.
- Food Supplements (Vitamins, Dietary Supplements, Foods for Special Medical Purposes) Food supplements encompassing vitamins, dietary supplements, and foods for special medical purposes, supplied to patients, pharmacists, and wholesalers across CIS markets, including through almedamedical.com.
Companies that use Almeda Pharmaceuticals Ag
Customer profileNamed customers2 records
Segments5 records
Ideal customer profiles2 records
Almeda Pharmaceuticals Ag technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Almeda Pharmaceuticals Ag partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Galen PharmacoreGalen Pharma, a privately-owned pharmaceutical sales and marketing company, signed an exclusive licensing deal with Almeda Pharmaceuticals AG. The agreement provides Almeda Pharma with exclusive rights to license Galen's PKU EASY Microtabs Plus across several markets including Ukraine, Moldova, Georgia, Armenia, Azerbaijan, and Kazakhstan. PKU Easy Microtabs Plus provides a phenylalanine-free protein substitute for individuals with Phenylketonuria, enriched with vitamins, minerals, and amino acids.
- Callion PharmacoreAlmeda Pharmaceuticals AG, a Swiss pharmaceutical company, and Callion Pharma, a company located in the USA, announced an exclusive partnership for the Commonwealth of Independent States (CIS) region. This collaboration aims to address the unique healthcare needs of rare disease patients, with exclusive distribution of Callion Pharma's innovative rare disease therapies, prioritizing introduction of essential medications to benefit Cystic Fibrosis patients in CIS countries.
Scale indicators3 records
Recent moves5 records
Expansion highlights4 records
Almeda Pharmaceuticals Ag competitors and assessment
Company assessmentEmerging players
- Swedish Orphan Biovitrum (Sobi): Specialty rare disease pharmaceutical company focused on rare diseases including metabolic and genetic disorders. Both companies target rare disease therapeutics (PKU, Cystic Fibrosis), though Sobi is a global developer with proprietary products while Almeda licenses and distributes for partners.
- Recordati Rare Diseases (Orphan Europe): Specialty rare disease division of Recordati focused on metabolic and rare disorders including PKU. Both companies serve the rare disease patient population in CIS and European markets with specialized therapies, though Recordati develops and markets proprietary products.
Broad incumbents
- Gedeon Richter: Hungarian-headquartered pharmaceutical company with deep CIS and Russian market presence. Both companies target specialty pharma and generics distribution in CIS markets; Gedeon Richter operates as a vertically integrated manufacturer with established regional scale.
- Zentiva: European generics manufacturer headquartered in Prague with significant CIS and Eastern European operations. Zentiva's branded generics portfolio and CIS market presence overlap directly with Almeda's oncology and specialty distribution model.
- KRKA: Slovenian pharmaceutical manufacturer with a strong CIS and Eastern European generics footprint. KRKA produces oncology and specialty generics similar to Almeda's MEDA line, but operates as an integrated manufacturer rather than a distribution-focused company.
- Polpharma: Polish pharmaceutical manufacturer with strong presence in CIS markets and Eastern Europe. Both companies focus on generics and specialty pharmaceuticals for the CIS region, though Polpharma is an integrated manufacturer rather than a distribution specialist.
- Hikma Pharmaceuticals: MENA-headquartered pharmaceutical company with growing presence in CIS and Eastern European markets. Both companies focus on branded generics and specialty pharmaceuticals for underserved regional markets.
- Teva Pharmaceutical Industries: Israeli-headquartered global generics leader with significant CIS and Eastern European operations. Teva's branded generics and specialty portfolio overlaps with Almeda's oncology MEDA line, though Teva operates globally with vastly greater scale.
- STADA Arzneimittel AG: European generics and specialty pharmaceutical company with established presence across CIS and Eastern European markets. Both companies operate in branded generics and specialty distribution, though STADA is far larger and serves broader geographies including Western Europe.
- Sandoz: Novartis' generics spin-off with global operations including Europe and CIS markets. Both companies distribute generic and specialty pharmaceuticals, though Sandoz operates as a fully integrated global manufacturer-distributor.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights5 records
Customer concentration
Almeda Pharmaceuticals Ag social profiles
Digital presenceAlmeda Pharmaceuticals Ag compliance and trust
Trust signalCompliance3 records
Almeda Pharmaceuticals Ag financial estimates
Financial estimateRevenue estimate
Valuation estimate
Almeda Pharmaceuticals Ag leadership team
Management profileNumber of profiles
Profiles1 record
Almeda Pharmaceuticals Ag funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Almeda Pharmaceuticals Ag M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Almeda Pharmaceuticals Ag
What does Almeda Pharmaceuticals Ag do?
Almeda Pharmaceuticals AG is a Swiss specialty pharmaceutical company that acquires exclusive licensing and distribution rights to international pharmaceutical products and distributes them across the CIS region. Its portfolio spans branded generic oncology drugs (the MEDA line), transplanthology, CNS, antimicrobic, and rare disease therapies, complemented by food supplements. The company also provides regulatory, supply-chain, and market-access services to manufacturers seeking entry into Eastern European and Central Asian markets.
Is Almeda Pharmaceuticals Ag a public or private company?
Almeda Pharmaceuticals Ag is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Almeda Pharmaceuticals Ag founded?
Almeda Pharmaceuticals Ag was founded in 2013. It employs 11 to 50 people.
Where is Almeda Pharmaceuticals Ag based?
Almeda Pharmaceuticals Ag is headquartered in Zug, Switzerland, in the Europe region.
How does Almeda Pharmaceuticals Ag make money?
Three revenue lines are on record. Licensing and Distribution Rights are the primary driver. The others are generic Pharmaceutical Products and market Entry Services.
Who are Almeda Pharmaceuticals Ag's main competitors?
Emerging players on record are Swedish Orphan Biovitrum (Sobi) and Recordati Rare Diseases (Orphan Europe). Broad incumbents are Gedeon Richter, Zentiva, KRKA, Polpharma, Hikma Pharmaceuticals, Teva Pharmaceutical Industries, STADA Arzneimittel AG and Sandoz.
Does Almeda Pharmaceuticals Ag have an API?
No public API is recorded for Almeda Pharmaceuticals Ag.
What industry is Almeda Pharmaceuticals Ag in?
Almeda Pharmaceuticals Ag's product category is Specialty Pharmaceutical Distribution & Licensing. Its primary akta.pro industry code is CRAOAHAD, Specialty Pharmacy & Biologics Distribution, with a secondary code of HLAGAMAD, Specialty Pharma & Biologics Distribution (GDP-compliant). Its NAICS code is 424210 and its SIC code is 5122.